Domofenogene zalfaparvovec

扎哌度莫基

Report date: 2023/10/26 16:15:12

Base Information

Drug NameDomofenogene zalfaparvovec
Drug Alias NameBMN 307 AAVBMN-307
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionGene transferencePhenylalanine hydroxylase modulators
TargetsPhenylalanine hydroxylase
Therapy Area/IndicationsPhenylketonurias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiomarin Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsPhenylketonurias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A